Myeloproliferative cancer JAK2 gene p.V617F diagnostics
The incidence of p. V617F mutations in the JAK2 gene is:
- over 95% of patients with polycythemia vera (PV)
- 55% of patients with essential thrombocythemia (ET)
- 65% of patients with primary myelofibrosis (PMF) primary myelofibrosis)
For more information:
Polycythemia vera
Essential thrombocythemia
Primary myelofibrosis
The test material should be collected using the sent PAXgene DNA blood CE IVD whole blood kit.
The collected material should be sent to the laboratory.
THE MATERIAL CAN BE STORED AT ROOM TEMPERATURE WITHOUT AFFECTING ITS QUALITY FOR UP TO 14 DAYS.
190.00 zł
Why is it worth testing?
Purpose of the test
Janus kinase 2 is a cytoplasmic tyrosine kinase and is part of a cytokine receptor-dependent signaling pathway leading to the activation of signal transducers and activators of transcription (STAT). The p.V617F mutation is the most common mutation in the JAK gene and causes constitutive activation of the JAK/STAT axis. JAK i powoduje konstytutywną aktywację osi JAK/STAT.
Indications for performing the test
Diagnosis of myeloproliferative tumours.
Still in doubt? Any questions?
We encourage you to contact us to resolve any doubts!
Napisz do nas, korzystając w formularza lub umów bezpłatną wstępną konsultacje
